



AETNA BETTER HEALTH®  
Coverage Policy/Guideline

Name: Liraglutide, Ozempic, and Trulicity Page: 1 of 4

Effective Date: 11/1/2024 Last Review Date: 10/2024

Applies to:	<input type="checkbox"/> Illinois	<input type="checkbox"/> Florida	<input checked="" type="checkbox"/> Florida Kids
	<input checked="" type="checkbox"/> New Jersey	<input checked="" type="checkbox"/> Maryland	<input type="checkbox"/> Michigan
	<input checked="" type="checkbox"/> Pennsylvania Kids	<input type="checkbox"/> Virginia	<input checked="" type="checkbox"/> Kentucky PRMD

**Intent:**

The intent of this policy/guideline is to provide information to the prescribing practitioner outlining the coverage criteria for Liraglutide, Ozempic, and Trulicity under the patient’s prescription drug benefit.

**Description:**

**Liraglutide**

Liraglutide is indicated:

- as an adjunct to diet and exercise to improve glycemic control in patients 10 years and older with type 2 diabetes mellitus.
- to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) in adults with type 2 diabetes mellitus and established cardiovascular disease.

Limitations of Use

- Liraglutide should not be used in patients with type 1 diabetes mellitus.
- Liraglutide contains liraglutide and should not be coadministered with other liraglutide-containing products.

Compendial Uses

Advanced chronic kidney disease (CKD) in adults with type 2 diabetes mellitus

Ozempic is indicated:

- as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
- to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction or non-fatal stroke) in adults with type 2 diabetes mellitus and established cardiovascular disease.

Limitations of Use

- Ozempic has not been studied in patients with a history of pancreatitis. Consider other antidiabetic therapies in patients with a history of pancreatitis.
- Ozempic is not indicated for use in patients with type 1 diabetes mellitus.

Compendial Uses

Advanced chronic kidney disease (CKD) in adults with type 2 diabetes mellitus

Trulicity is indicated:

- as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.



AETNA BETTER HEALTH®  
Coverage Policy/Guideline

Name:	Liraglutide, Ozempic, and Trulicity	Page:	2 of 4
Effective Date:	11/1/2024	Last Review Date:	10/2024
Applies to:	<input type="checkbox"/> Illinois <input checked="" type="checkbox"/> New Jersey <input checked="" type="checkbox"/> Pennsylvania Kids	<input type="checkbox"/> Florida <input checked="" type="checkbox"/> Maryland <input type="checkbox"/> Virginia	<input checked="" type="checkbox"/> Florida Kids <input type="checkbox"/> Michigan <input checked="" type="checkbox"/> Kentucky PRMD

- to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) in adults with type 2 diabetes mellitus who have established cardiovascular disease or multiple cardiovascular risk factors.

#### Limitations of Use

- Trulicity has not been studied in patients with a history of pancreatitis. Consider other antidiabetic therapies in patients with a history of pancreatitis.
- Trulicity should not be used in patients with type 1 diabetes mellitus.
- Trulicity has not been studied in patients with severe gastrointestinal disease, including severe gastroparesis and is therefore not recommended in these patients.

#### Compendial Uses

Advanced chronic kidney disease (CKD) in adults with type 2 diabetes mellitus

### **Applicable Drug List:**

Formulary with Step Therapy: Liraglutide, Ozempic, and Trulicity

### **Policy/Guideline:**

If the patient has filled at least 60 days of metformin within the past 180 days under the Aetna Better Health prescription benefit and has a diagnosis of Type 2 Diabetes, then the requested drug will be paid under that prescription benefit. If the patient does not meet the initial step therapy criteria, then the claim will reject with a message indicating that a prior authorization (PA) is required. The prior authorization criteria would then be applied to requests submitted for evaluation to the PA unit.

### **Coverage Criteria**

Authorization may be granted for a diagnosis of type 2 diabetes mellitus when the patient has NOT been receiving a stable maintenance dose of the requested drug for at least 3 months when ONE of the following criteria are met:

- The patient experienced an inadequate treatment response, intolerance, or has a contraindication to metformin
- The patient requires combination therapy AND has an A1C of 7.5 percent or greater
- The patient has established cardiovascular disease and the following criteria is met:
  - Ozempic (semaglutide), Trulicity (dulaglutide), or liraglutide
- The patient has multiple cardiovascular risk factors and the following criteria is met:
  - The request is for Trulicity (dulaglutide)
- The patient has a diagnosis of advanced chronic kidney disease (CKD) (estimated glomerular filtration rate [eGFR] less than 30 mL/min/1.73m<sup>2</sup>) and the following criteria is met:
  - The request is for Ozempic (semaglutide), Trulicity (dulaglutide) or liraglutide



AETNA BETTER HEALTH®  
Coverage Policy/Guideline

Name:	Liraglutide, Ozempic, and Trulicity	Page:	3 of 4
Effective Date:	11/1/2024	Last Review Date:	10/2024
Applies to:	<input type="checkbox"/> Illinois <input checked="" type="checkbox"/> New Jersey <input checked="" type="checkbox"/> Pennsylvania Kids	<input type="checkbox"/> Florida <input checked="" type="checkbox"/> Maryland <input type="checkbox"/> Virginia	<input checked="" type="checkbox"/> Florida Kids <input type="checkbox"/> Michigan <input checked="" type="checkbox"/> Kentucky PRMD

### Continuation of Therapy

Authorization may be granted for a diagnosis of type 2 diabetes mellitus when the patient has been receiving a stable maintenance dose of the requested drug for at least 3 months when ONE of the following criteria are met:

- The patient has demonstrated a reduction in A1C since starting this therapy
- The patient has established cardiovascular disease and the following criteria is met:
  - Ozempic (semaglutide), Trulicity (dulaglutide), or liraglutide
- The patient has multiple cardiovascular risk factors and the following criteria is met:
  - The request is for Trulicity (dulaglutide)
- The patient has a diagnosis of advanced chronic kidney disease (CKD) (estimated glomerular filtration rate [eGFR] less than 30 mL/min/1.73m<sup>2</sup>) and the following criteria is met:
  - The request is for Ozempic (semaglutide), Trulicity (dulaglutide) or liraglutide

### Approval Duration and Quantity Restrictions:

**Approval:** 12 months

**Quantity Level Limit:** Reference Formulary for drug specific quantity level limits

### References:

1. Ozempic [package insert]. Plainsboro, NJ: Novo Nordisk Inc.; September 2023.
2. Trulicity [package insert]. Indianapolis, IN: Eli Lilly and Company; December 2022.
3. Victoza [package insert]. Plainsboro, NJ: Novo Nordisk Inc.; July 2023.
4. Lexicomp Online, AHFS DI (Adult and Pediatric) Online. Waltham, MA: UpToDate, Inc.; 2024. <https://online.lexi.com>. Accessed March 4, 2024.
5. Micromedex (electronic version). Merative, Ann Arbor, Michigan, USA. Available at: <https://www.micromedexsolutions.com/> (cited: 03/04/2024).
6. Blonde L, Umpierrez GE, Reddy SS et. al. American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan – 2022 Update. *Endocrine Practice* 28 (2022) 923-1049.
7. Davies MJ, Aroda VR, Collins BS, et. al. Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). *Diabetes Care*. 2022;45(11):2753-2786.
8. American Diabetes Association Professional Practice Committee. American Diabetes Association, Standards of Care in Diabetes – 2024. *Diabetes Care*. 2024;47(Suppl. 1):S1-S322.
9. Heidenreich PA, Bozkurt B, Aguilar D et. al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. *J Am Coll Cardiol*. 2022;79:e263-e421.
10. Kittleson MM, Panjrath GS, Amancherla K et. al. 2023 ACC expert consensus decision pathway on management of heart failure with preserved ejection fraction: a report of the American College of Cardiology Solution Set Oversight Committee. *J Am Coll Cardiol*. 2023;81(18):1835-1878.



AETNA BETTER HEALTH®  
Coverage Policy/Guideline

Name: Liraglutide, Ozempic, and Trulicity Page: 4 of 4

Effective Date: 11/1/2024 Last Review Date: 10/2024

Applies to:	<input type="checkbox"/> Illinois	<input type="checkbox"/> Florida	<input checked="" type="checkbox"/> Florida Kids
	<input checked="" type="checkbox"/> New Jersey	<input checked="" type="checkbox"/> Maryland	<input type="checkbox"/> Michigan
	<input checked="" type="checkbox"/> Pennsylvania Kids	<input type="checkbox"/> Virginia	<input checked="" type="checkbox"/> Kentucky PRMD

11. Maddox TM, Januzzi JL Jr, Allen LA, et. al. 2024 ACC expert consensus decision pathway for treatment of heart failure with reduced ejection fraction: a report of the American College of Cardiology Solution Set Oversight Committee. *J Am Coll Cardiol* 2024;XX:XXX-XX.
12. Samson SL, Vellanki P, Blonde L et. al. American Association of Clinical Endocrinology Consensus Statement: Comprehensive Type 2 Diabetes Management Algorithm – 2023 Update. *Endocrine Practice* 2023;29(5):P305-340.